Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 9/2019

01-09-2019 | Semaglutide | Diabetes and Cardiovascular Disease (N Wong, Section Editor)

Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease

Authors: Devinder S. Dhindsa, Anurag Mehta, Pratik B. Sandesara, Aneesha Thobani, Stephen Brandt, Laurence S. Sperling

Published in: Current Cardiology Reports | Issue 9/2019

Login to get access

Abstract

Purpose of Review

This review will serve to highlight the clinical rationale used in the selection of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) or glucagon-like peptide 1 receptor agonists (GLP1-ra).

Recent Findings

SGLT2-i and GLP1-ra are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit in multiple cardiovascular outcomes trials (CVOTs), with benefits that are consistent across class of medication.

Summary

Diabetes is a major risk factor for morbidity and mortality from cardiovascular disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide 1 receptor agonists (GLP1-ra) are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit. Given the unique side effect and benefit profiles, appropriate consideration of these agents with a focus on cardiovascular risk reduction requires an individualized approach.
Literature
1.
Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J. 2007;28(5):540–5.CrossRef
2.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet (London, England) 1998;352(9131):837–53.
3.
Effects of intensive glucose lowering in type 2 diabetes. 2008;358(24):2545–59.
4.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. 2008;358(24):2560–72.
5.
•• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28 This study was the first cardiovascular outcomes trial to show a benefit of an anti-hyperglycemic medication in cardiovascular outcomes. Empagliflozin demonstrated a large and surprising benefit in cardiovascular endpoints as compared with placebo. CrossRef
6.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. 2017;377(7):644–57.
7.
Fitchett D, investigators tE-ROt, Zinman B, investigators tE-ROt, Wanner C, investigators tE-ROt, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–34.CrossRef
8.
Rådholm K, Figtree G, Perkovic V, Solomon Scott D, Mahaffey Kenneth W, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018;138(5):458–68.CrossRef
9.
• Kato Eri T, Silverman Michael G, Mosenzon O, Zelniker Thomas A, Cahn A, Furtado Remo HM, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–36. This study showed that the benefit of the SGLT2 inhibitors is particularly evident in heart failure with reduced ejection fraction. CrossRef
10.
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–26.CrossRef
11.
Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–8.CrossRef
12.
Dhindsa DS, Sandesara PB, Shapiro MD. The intersection of diabetes and cardiovascular disease—a focus on new therapies. Frontiers in Cardiovascular Medicine. 2018;5:160.
13.
Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–22.CrossRef
14.
Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23.CrossRef
15.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.CrossRef
16.
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–97.CrossRef
17.
Kosiborod M, Cavender Matthew A, Fu Alex Z, Wilding John P, Khunti K, Holl Reinhard W, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Circulation. 2017;136(3):249–59.CrossRef
18.
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14.CrossRef
19.
• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–22 This study was the first to show cardiovascular benefit among the GLP1 receptor agonists, showing a reduction in cardiovascular mortality in those randomized to liraglutide as compared with placebo. CrossRef
20.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRef
21.
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.CrossRef
22.
Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181–7.CrossRef
23.
•• Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72(24):3200–23. Major statement by the American College of Cardiology urging the consideration and use of SGLT-2 inhibitors and GLP-1 receptor agonists among cardiologists.
24.
Tanaka A, Node K. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc Diabetol. 2017;16(1):129.CrossRef
25.
Trujillo JM, Nuffer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy. 2017;37(4):481–91.CrossRef
26.
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42.CrossRef
27.
Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–84.CrossRef
28.
Storgaard H, Cold F, Gluud LL, Vilsboll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906–8.CrossRef
29.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86.CrossRef
30.
Vilsboll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simo R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–97.CrossRef
31.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004–16.CrossRef
Metadata
Title
Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease
Authors
Devinder S. Dhindsa
Anurag Mehta
Pratik B. Sandesara
Aneesha Thobani
Stephen Brandt
Laurence S. Sperling
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 9/2019
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-019-1197-6

Other articles of this Issue 9/2019

Current Cardiology Reports 9/2019 Go to the issue

Regenerative Medicine (SM Wu, Section Editor)

Engineering Functional Cardiac Tissues for Regenerative Medicine Applications

Echocardiography (JM Gardin and AH Waller, Section Editors)

Echocardiographic Diastolic Stress Testing: What Does It Add?

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Lp(a): Addressing a Target for Cardiovascular Disease Prevention

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Effectiveness of Changes in Diet Composition on Reducing the Incidence of Cardiovascular Disease

Regenerative Medicine (SM Wu, Section Editor)

Bioprinting Approaches to Engineering Vascularized 3D Cardiac Tissues

New Therapies for Cardiovascular Disease (AA Bavry, Section Editor)

Current Role of the CardioMEMS Device for Management of Patients with Heart Failure